(88 days)
Not Found
No
The summary describes standard physiological monitoring technology (transcutaneous PCO2, SpO2, pulse rate) and mentions Masimo SET signal extraction technology, which is a known signal processing method, not AI/ML. There are no mentions of AI, ML, or related concepts, nor descriptions of training or test sets typically associated with AI/ML development.
No
The device is described as a "Monitoring System" for physiological parameters (PCO₂, SpO2, and Pulse Rate). Its function is to measure and display these values, which is for diagnostic or informational purposes, not for direct treatment or therapy.
No
The device is described as a "Monitoring System" designed for "simultaneous continuous monitoring" of physiological parameters (PCO2, SpO2, and Pulse Rate). While monitoring is often a part of diagnosis, the primary function described is continuous measurement rather than the identification of a disease state.
No
The device description explicitly lists hardware components such as a "Tosca Monitor," "Tosca Sensor," "supplies for the sensor preparation," "supplies for the sensor attachment," and a "gas mixture for the sensor calibration." This indicates it is a hardware-based medical device with integrated software, not a software-only device.
Based on the provided information, the Linde TOSCA 500 Monitoring System is an IVD (In Vitro Diagnostic).
Here's why:
- Monitoring of physiological parameters: The device monitors transcutaneous PCO₂, functional oxygen saturation (SpO2), and pulse rate. These are physiological parameters that provide information about a patient's health status.
- Clinical comparative studies: The performance studies described involve comparing the device's measurements (transcutaneous PCO2 and arterial hemoglobin saturation) with values obtained from arterial blood gas values and arterial blood samplings with a co-oximeter. These are laboratory tests performed on biological samples (blood).
- Comparison to laboratory results: The core of the performance evaluation relies on comparing the device's readings to results obtained from in vitro diagnostic procedures (blood gas analysis and co-oximetry). This is a key characteristic of devices that are considered IVDs or are used in conjunction with IVD results for clinical decision-making.
While the device itself is applied externally to the ear lobe, its function is to provide information that is directly compared to and used in the context of in vitro diagnostic results (blood tests). This close relationship and reliance on comparison with laboratory data strongly indicate its classification as an IVD.
N/A
Intended Use / Indications for Use
The Linde TOSCA 500 Monitoring System is designed for the simultaneous continuous monitoring of transcutaneous PCO₂, functional oxygen saturation SpO2 and Pulse Rate in adults and pediatrics.
Product codes (comma separated list FDA assigned to the subject device)
DPZ, LKD
Device Description
The Linde TOSCA 500 Monitoring System is designed for the simultaneous continous monitoring of transcutaneous PCO2 functional oxygen saturation SpO2 and pulse rate, using a single sensor (Tosca Sensor) applied to the ear lobe.
The system consists of a Tosca Monitor equipped with an integrated calibration unit which allows a fully automatic calibration of the PCO2 part of the sensor and also provides a storage facility for the sensor, and with the Masimo SET signal extraction technology for the calculation of the functional oxygen saturation and the pulse rate ; a Tosca Sensor comprising the elements of an electrochemical Stow-Severinghaus-type carbon dioxide sensor and of an optical pulse oximetry sensor; supplies for the sensor preparation; supplies for the sensor attachment at the ear lobe; and a gas mixture for the sensor calibration.
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
Ear lobe
Indicated Patient Age Range
Adults and pediatrics
Intended User / Care Setting
Not Found
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)
Clinical comparative studies between transcutaneous PCO2 and arterial blood gas values, using the TOSCA Monitoring System were performed on adults and infants. The results show that the TOSCA System performs as intended and that a good correlation exists between trancutaneous PCO2 and arterial blood qas values.
Clinical studies using the TOSCA Monitoring System were performed on healthy adults volunteers subjected to induced hypoxia measuring the arterial hemoglobin saturation values and comparing these values to the values determined from arterial blood samplings with a co-oximeter. The results show that the TOSCA System performs as intended and that the specified saturation accuracy is met.
Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)
Not Found
Predicate Device(s): If the device was cleared using the 510(k) pathway, identify the Predicate Device(s) K/DEN number used to claim substantial equivalence and list them here in a comma separated list exactly as they appear in the text. List the primary predicate first in the list.
Reference Device(s): Identify the Reference Device(s) K/DEN number and list them here in a comma separated list exactly as they appear in the text.
Not Found
Predetermined Change Control Plan (PCCP) - All Relevant Information for the subject device only (e.g. presence / absence, what scope was granted / cleared under the PCCP, any restrictions, etc).
Not Found
§ 868.2480 Cutaneous carbon dioxide (PcCO2) monitor.
(a)
Identification. A cutaneous carbon dioxide (PcCO2) monitor is a noninvasive heated sensor and a pH-sensitive glass electrode placed on a patient's skin, which is intended to monitor relative changes in a hemodynamically stable patient's cutaneous carbon dioxide tension as an adjunct to arterial carbon dioxide tension measurement.(b)
Classification. Class II (special controls). The special control for this device is FDA's “Class II Special Controls Guidance Document: Cutaneous Carbon Dioxide (PcCO2) and Oxygen (PcO2) Monitors; Guidance for Industry and FDA.” See § 868.1(e) for the availability of this guidance document.
0
LINDE MEDICAL SENSORS AG
Image /page/0/Picture/3 description: The image shows the word "Linde" in a stylized, cursive font. The "L" has a large, decorative swirl at the top, and the rest of the letters are connected in a flowing script. The word is in black and stands out against a white background.
510(k) Summary
| Submitted by: | Linde Medical Sensors AG
Austrasse 25
4051 Basel - Switzerland
Phone: 011 41 61 278 82 07
Fax: 011 41 61 278 81 81 |
|----------------------------------|--------------------------------------------------------------------------------------------------------------------------------|
| Contact: | Jean-Pierre Palma
Head of Mechanical Engineering / Regulatory Affairs |
| Date Summary prepared: | October 20, 2004 |
| Trade Name: | TOSCA 500 PCO2, SpO2 and Pulse Rate Monitoring System |
| Common Name: | Cutaneous Gas Monitor / Pulse Oximeter |
| Classification Name: | Monitor Carbon Dioxide Cutaneous (73LKD) / Oximeter (74DQA |
| Substantially Equivalent Device: | Tosca PCO2, SpO2 and Pulse Rate Monitoring System
510(k) Number: K032291 |
Description of the TOSCA 500 PCO2, SpO2 and Pulse Rate Monitoring System
The Linde TOSCA 500 Monitoring System is designed for the simultaneous continous monitoring of transcutaneous PCO2 functional oxygen saturation SpO2 and pulse rate, using a single sensor (Tosca Sensor) applied to the ear lobe.
The system consists of a Tosca Monitor equipped with an integrated calibration unit which allows a fully automatic calibration of the PCO2 part of the sensor and also provides a storage facility for the sensor, and with the Masimo SET signal extraction technology for the calculation of the functional oxygen saturation and the pulse rate ; a Tosca Sensor comprising the elements of an electrochemical Stow-Severinghaus-type carbon dioxide sensor and of an optical pulse oximetry sensor; supplies for the sensor preparation; supplies for the sensor attachment at the ear lobe; and a gas mixture for the sensor calibration.
Intended Use
The Linde TOSCA 500 Monitoring System is designed for the simultaneous continuous monitoring of transcutaneous PCO2, functional oxygen saturation SpO2 and pulse rate in adults and pediatrics.
Principles of Operation
The Linde Tosca is used for the simultaneous continuous monitoring of transcutaneous PCO2. functional oxygen saturation SpO2 and pulse rate, using a single sensor (Tosca Sensor) applied to the ear lobe.
1
Transcutaneous measurement of PCO2 makes use of the fact that carbon dioxide gas is able to Transculanced medical one skin and can be detected by a sensor at the skin surface. By ulliuse through body trouc and allin and is induced, which increases the supply of arterial blood warming up the ochoor, a Usak of the sensor. The PCO2 part of the Tosca sensor consists of a to the deman capillary bod bolow the 60% is measured by determining the pH of an electrolyte Stow-Oc vehinghade type Sloothoodional to the logarithm of the PCO2 change. The pH is solution. A change in pr r is proponial to ween a miniaturized glass pH electrode and an Ag/AgCl delemined by modouning the povided within a thin hydrophilic spacer, which is placed over the sensor surface and is coupled to the skin via a highly gas permeable hydrophobic over the sensor sunded and 10 couple a gas of a known CO2 concentration. The slope (change of potential with PCO2) is preset in the sensor memory.
The principle of the SpO2 measurement is based on the difference in the light absorption The principle of the Open model in its oxygenated and reduced forms. The SpO2 part of the TOSCA sensor consists of two light emitting diodes, a red (660 nm) and an infrared (880 nm), and a School online of two light originating from the diodes passes through the ear lobe and is redirected at the opposite side by a light reflecting material. The light received by the photo detector is converted to electrical signals which are analyzed by the monitor. The signals containing pulsatile components which are caused by variations in blood volume synchronous with cardiac action reflecting inflowing arterial blood and fluctuating absorbance of venous blood due to patient motion are analysed with the Masimo SET Signal Extraction Technology incorporated in the TOSCA 500 Monitor. Because oxyhemoglobin differ in light absorption, the amount of red and infrared light absorbed by the blood is related to hemoglobin oxygen saturation. The Masimo SET signal processing decomposes the red and infrared pulsatile absorbance signals into an arterial signal plus a noise component and calculates the ratio of the arterial signals without noise. The ratio of the two arterial pulse added absorbance signals and its value is used to find the SpO2 saturation in an empirically derived equation in the Masimo Set software. The values in the look-up table are based upon human blood studies against a laboratory co-oximeter on healthy adult volunteers in induced hypoxia states.
Environmental Testing
Applicable environmental, electrical, EMC and mechanical Testing per Reviewers Guidance for Premarket Submissions - November 1993 were performed and the TOSCA 500 Monitoring System passed all tests.
Biocompatibility Testing
All patient contact materials were tested as Surface Devices with skin contact for prolonged contact duration (24 hours to 30 days) as defined in ISO-10993-1:1992 Biological Evaluation of Medical Devices - Part 1: Guidance on Selection of Tests. All patient contacting material passed.
Non clinical tests performed that support a determination of substantial equivalence
The TOSCA 500 Monitoring System was subjected to bench testing that determined the transcutaneous PCO2 performances according to IEC 60601-2-23 and IEC 60601-3-1.
The TOSCA 500 Monitoring System was subjected to bench testing using a simulator that determined the saturation and pulse rate performance accuracies under the ranges specified.
2
Clinical tests performed that support a determination of substantial equivalence
Clinical comparative studies between transcutaneous PCO2 and arterial blood gas values, using the TOSCA Monitoring System were performed on adults and infants. The results show that the TOSCA System performs as intended and that a good correlation exists between trancutaneous PCO2 and arterial blood qas values.
Clinical studies using the TOSCA Monitoring System were performed on healthy adults volunteers subjected to induced hypoxia measuring the arterial hemoglobin saturation values and comparing these values to the values determined from arterial blood samplings with a co-oximeter. The results show that the TOSCA System performs as intended and that the specified saturation accuracy is met.
Conclusion
The results of the environmental, bench and clinical testing demonstrate that the TOSCA 500 PCO2 SpO2 and Pulse Rate Monitoring System and accessories are safe, effective and performs as well as the predicated device.
Austrasse 25 Teleton +41 1016 : 278 81 13 CH-4051 Base Telefax +41 (0)61 278 81 81
3
MAR 4 - 2005
Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850
Mr. Jean-Pierre Palma Mr. Jour Prochanical Engineering/Regulatory Affairs Linde Medical Sensors AG Austrasse 25 Basel, 4051 SWITZERLAND
Re: K043357
R043337
Trade/Device Name: TOSCA 500 PCO2, SpO2 and Pulse Rate Monitoring System Regulation Number: 870.2710 Regulation Name: Ear Oximeter Regulatory Class: II Product Code: DPZ, LKD Dated: February 4, 2005 Received: February 7, 2005
Dear Mr. Palma:
We have reviewed your Section 510(k) premarket notification of intent to market the device we nave reviewed your and have determined the device is substantially equivalent (for the fererenced above and have and in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device mendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket the Federal I 60a; Drag, Drag, therefore, market the device, subject to the general approvisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting (1 Writ), it may of the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
4
Page 2 – Mr. Ferguson
Please be advised that FDA's issuance of a substantial equivalence determination does not Please be advised that PDA $ Issualics of a substition of extent of ther requirements
mean that FDA has made a determination that your devices Federal agencies mean that FDA has made a decemination that your and inistered by other Federal agencies.
of the Act or any Federal statutes and regulations and mited to: registration of the Act or any Federal statues and reginations, but not limited to: registration
You must comply with all the Act's requirements, including, but not ice You must comply with an the Act 3 requirement 801); good manufacturing practice
and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice and listing (21 CPK Part 807), labelling (21 OFF Part 820); and if
requirements as set forth in the quality systems (QS) regulation (21 CFR Part 821); and if requirements as set form in the quality systems (Sections 531-542 of the Act);
applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
This letter will allow you to begin marketing your device as described in your Section 510(k) I his letter will anow you to begin malies.ing your alence of your device to a
premarket notification. The FDA finding of substantial equivalence and this and premarket notification. The PDA maing of cases and the your device and thus, permits your device to proceed to the market.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), If you desire specific atvice for your de need on the more in the regulation prease contact the Other or Comphanes and (21CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the may obtain of Small Manufacturers, International and Consumer Assistance at its toll-free Division of 01638-2041 or (301) 443-6597 or at its Internet address http://www.fda.gov/cdrh/industry/support/index.html.
Sincerely yours,
Sutie Michie md.
Chiu Lin, Ph.D. Director Division of Anesthesiology, General Hospital, Infection Control and Dental Devices Office of Device Evaluation Center for Devices and Radiological Health
Enclosure
5
Indications for Use
510(k) Number (if known):
Device Name: TOSCA 500 PCO2, SpO2 and Pulse Rate Monitoring System
Indications For Use:
The Linde TOSCA 500 Monitoring System is designed for the simultaneous continuous monitoring of transcutaneous PCO₂, functional oxygen saturation SpO2 and Pulse Rate in adults and pediatrics.
X Prescription Use (Part 21 CFR 801 Subpart D) AND/OR
Over-The-Counter Use (21 CFR 807 Subpart C)
(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)
Concurrence of CDRH, Office of Device Evaluation (ODE)
726-16727 con of Andrew : clogy, General Hospital, Insusion Contral, Denell Devices . 19(3) Number ___
Page 1 of ____________________________________________________________________________________________________________________________________________________________________